Clinically, there are EGFR–tyrosine kinase inhibitor-targeted therapies for EGFR, which can inhibit tyrosine kinase, inhibit epidermal growth factor upregulation, or delay and inhibit tumor invasion or metastasis, and these therapies have been proven to be effective in the treatment of NSCLC [16]. The gene discussed is EGFR; the disease is neoplasm.